Association of the T+294C polymorphism in PPAR δ with low HDL cholesterol and coronary heart disease risk in women

International Journal of Medical Sciences

Volumn 3, Issue 3, 2006, Pages 108-111

  Aberle, Jens ^a   Hopfer, Inga ^a   Beil, Frank Ulrich ^a   Seedorf, Udo ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ALLELE; ARTICLE; BODY MASS; CONTROLLED STUDY; CORONARY RISK; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS;

EID: 33745819570     PISSN: 14491907     EISSN: 14491907     Source Type: Journal    
DOI: 10.7150/ijms.3.108     Document Type: Article

References (12)

1. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med 2004; 4:1-7
2. Reddy JK and Hashimoto T. Peroxisomal β-Oxidation and peroxisome proliferator activated receptor α: an adaptive metabolic system. Annu Rev Nutr 2001; 21: 193-230.
3. Spiegelman BM and Flier JS. Adipogenesis and obesity: rounding the big picture. Cell 1996; 87:377-389
4. Skogsberg J, Kannisto R, Roshani L, Gagne E, Hamsten A, Larsson C, Ehrenborg E. Characterization of the human peroxisome proliferator activated receptor delta gene and its expression. Int J Mol Med. 2000; 6: 73-81.
5. Olivier WR, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE. A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proc Nat Acad Sci USA 2001; 98: 5306-5311.
6. Leibowitz MD, Fievet C, Hennuyer N, Peinado-Onsurbe J, Duez H, Bergera J, Cullinan CA, Sparrow CP, Baffic J, Berger GD, Santini C, Marquis RW, Tolman RL, Smith RG, Moller DE, Auwerx J. Activation of PPAR delta alters lipid metabolism in db/db mice. FEBS Lett. 2000; 473(3): 333-336.
7. Luquet S, Lopez-Soriano J, Holst D, Fredenrich A, Melki J, Rassoulzandegan M, Grimaldi PA. Peroxisome proliferator-activated receptor δ controls muscle development and oxidative capability. FASEB. 2003; 17: 2299-2301.
8. Skogsberg J, Kannisto K, Cassel TN, Hamsten A, Eriksson P, Ehrenborg E. Evidence That Peroxisome Proliferator-Activated Receptor Delta Influences Cholesterol Metabolism in Men. Arterioscler Thromb Vasc Biol 2003; 23: 637-643.
9. Skogsberg J, McMahon AD, Karpe F, Hamsten A, Packard CJ, Ehrenborg E. Peroxisome proliferator activated receptor delta genotype in relation to cardiovascular risk factors and risk of coronary heart disease in hypercholesterolaemic men. J Int Med 2003; 254: 597-604.
10. Rust S, Funke H, Assmann G. Mutagenically separated PCR (MS-PCR): a highly specific one step procedure for easy mutation detection. Nucl A Res 1991;21: 3623-3629.
11. Chen S, Tsybouleva N, Ballantyne CM, Gotto AM, Marian AJ. Effects of PPARα, γ and δ haplotypes on plasma levels of lipids and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study. Pharmacogenet. 2004; 14:61-71.
12. Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC. Apolipoprotein E polymorphism and cardiovascular disease. Am J Epidemiol. 2002; 155:487-495.